Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy

Pharmacogenomics

Volumn 13, Issue 14, 2012, Pages 1609-1619

  Biason, Paola ^a   Visentin, Michele ^b   Talamini, Renato ^a   Stopar, Alex ^a   Giorda, Giorgio ^a   Lucia, Emilio ^a   Campagnutta, Elio ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

EOC; epithelial ovarian cancer; OS; overall survival; platinum; polymorphism; thymidylate synthase; TYMS

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GENOMIC DNA; MESSENGER RNA; PACLITAXEL; PLATINUM DERIVATIVE; THYMIDYLATE SYNTHASE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EVENT FREE SURVIVAL; FEMALE; GENE; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOME SIZE; GENOTYPE; HUMAN; INDEL MUTATION; OVARY CARCINOMA; OVERALL SURVIVAL; PHARMACOGENETICS; PROTEIN EXPRESSION; THYMIDYLATE SYNTHASE GENE; TSER GENE; VARIABLE NUMBER OF TANDEM REPEAT; WILD TYPE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, PHARMACOLOGICAL; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; PROGNOSIS; THYMIDYLATE SYNTHASE;

EID: 84869047966     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.136     Document Type: Article

References (40)

1. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 351(24), 2519-2529 (2004).
2. Piver MS. Ovarian carcinoma. A decade of progress. Cancer 54(Suppl. 11), S2706-S2715 (1984).
3. Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5fluorouracil in human colorectal and gastric tumors. Cancer Res. 55(7), 1407-1412 (1995).
4. Leichman CG. Predictive and prognostic markers in gastrointestinal cancers. Curr. Opin Oncol. 13(4), 291-299 (2001).
5. Mizutani Y, Wada H, Yoshida O et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin. Cancer Res. 9(4), 1453-1460 (2003).
6. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, Nomura Y. Clinical significance of thymidylate synthase expression in bladder cancer. Int. J. Urol. 9(7), 368-376 (2002).
7. Pestalozzi BC, Peterson HF, Gelber RD et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J. Clin. Oncol. 15(5), 1923-1931 (1997).
8. Shintani Y, Ohta M, Hirabayashi H et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int. J. Cancer 104(6), 790-795 (2003).
9. Suzuki M, Tsukagoshi S, Saga Y, Ohwada M, Sato I. Enhanced expression of thymidylate synthase may be of prognostic importance in advanced cervical cancer. Oncology 57(1), 50-54 (1999).
10. Edler D, Hallstrom M, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer. Clin. Cancer Res. 6(4), 1378-1384 (2000).
11. Takizawa M, Kawakami K, Obata T et al. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol. Rep. 15(6), 1533-1539 (2006).
12. Scanlon KJ , Kashani-Sabet M. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proc. Natl Acad. Sci. USA 85(3), 650-653 (1988).
13. Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem. Pharmacol. 37(24), 4597-4600 (1988).
14. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res. 48(20), 5713-5716 (1988).
15. Wang C, Weng Y, Wang H, Shi Y, Ma D. Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer. J. Huazhong. Univ. Sci. Technolog. Med. Sci. 30(4), 494-499 (2010).
16. Skibola CF, Forrest MS, Coppede F et al. Polymorphisms and haplotypes in folatemetabolizing genes and risk of non-Hodgkin lymphoma. Blood 104(7), 2155-2162 (2004).
17. Mandola MV, Stoehlmacher J, Zhang W et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14(5), 319-327 (2004).
18. Pullmann R Jr, Abdelmohsen K, Lal A, Martindale JL, Ladner RD, Gorospe M. Differential stability of thymidylate synthase 3'-untranslated region polymorphic variants regulated by AUF1. J. Biol. Chem. 281(33), 23456-23463 (2006).
19. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1(1), 65-70 (2001).
20. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct. Funct. 20(3), 191-197 (1995).
21. Kawakami K, Omura K, Kanehira E, Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res. 19(4B), 3249-3252 (1999).
22. Kawakami K, Salonga D, Park JM et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer Res. 7(12), 4096-4101 (2001).
23. Mandola MV, Stoehlmacher J, Muller-Weeks S et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF1 binding and alters transcriptional activity. Cancer Res. 63(11), 2898-2904 (2003).
24. Kawakami K, Watanabe G. Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. Cancer Res. 63(18), 6004-6007 (2003).
25. Lurje G, Zhang W, Yang D et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet. Genomics 18(2), 161-168 (2008).
26. Hitre E, Budai B, Adleff V et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet. Genomics 15(10), 723-730 (2005).
27. Ulrich CM, Bigler J, Bostick R, Fosdick L, Potter JD. Thymidylate synthase promoter polymorphism, interaction with folate intake, and risk of colorectal adenomas. Cancer Res. 62(12), 3361-3364 (2002).
28. Gusella M, Frigo AC, Bolzonella C et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br. J. Cancer 100(10), 1549-1557 (2009).
29. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK. Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet. Genomics 22(4), 290-304 (2012).
30. Lenz HJ, Leichman CG, Danenberg KD et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol. 14(1), 176-182 (1996).
31. Chu E, Allegra CJ. The role of thymidylate synthase in cellular regulation. Adv. Enzyme Regul. 36, 143-163 (1996).
32. Rahman L, Voeller D, Rahman M et al. Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 5(4), 341-351 (2004).
33. Ruzzo A, Graziano F, Loupakis F et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J. 8(4), 278-288 (2008).
34. Fernandez-Contreras ME, Sanchez- Hernandez JJ, Gonzalez E et al. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients. Int. J. Oncol. 34(1), 219-229 (2009).
35. Gosens MJ, Moerland E, Lemmens VP, Rutten HT, Tan-Go I, van den Brule AJ. Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer. Int. J. Cancer 123(8), 1941-1949 (2008).
36. Etienne-Grimaldi MC, Formento JL, Francoual M et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res. 14(15), 4830- 4835 (2008).
37. Kealey C, Brown KS, Woodside JV et al. A common insertion/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations. Hum. Genet. 116(5), 347-353 (2005).
38. Bast RC Jr. Molecular approaches to personalizing management of ovarian cancer. Ann. Oncol. 22(Suppl. 8), viii5- viii15 (2011).
39. Hall M, Rustin G. Recurrent ovarian cancer: when and how to treat. Curr. Oncol. Rep. 13(6), 459-471 (2011).
40. Geurts SM, de Vegt F, van Altena AM et al. Considering early detection of relapsed ovarian cancer: a review of the literature. Int. J. Gynecol. Cancer 21(5), 837-845 (2011).